[Significance of tumor markers in the treatment of cancer: hematologic malignancy].
Hematologic malignancies, such as acute leukemia and malignant lymphoma. Respond well to cancer chemotherapy. Therefore, it is important to monitor the state of response to chemotherapy as well as to determine the complete disappearance of the tumor and to predict early detection of recurrence in routine clinical work by estimation of tumor marker levels. Although changes in the levels of paraprotein in multiple myeloma have been utilized for monitoring the responsiveness to chemotherapy, since the amounts of paraprotein are directly proportional to the number of myeloma cells, in other hematologic malignancies there are no tumor markers for monitoring the clinical course, for detecting the presence of minimal residual disease, or for predicting disease recurrence. In the future it is expected that developments in biotechnology create a large number of reagents including 'oncogene'-related markers or 'oncogene' products for application to the diagnosis and treatment of cancer patients.
Sampi
K
K
Saitama Cancer Center, Hematology Clinic.
D000208:Acute Disease; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D009101:Multiple Myeloma / Q000628:therapy; D011379:Prognosis; D012074:Remission Induction
D014408:Biomarkers, Tumor; D007770:L-Lactate Dehydrogenase